Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findingsStefan Kubicka, Christophe Borg, Javier Sastre et al.|Annals of Oncology|2013Cited by 104
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial datasetJosef Thaler, Mohamed-Ayman Zawadi, Richard Greil et al.|Annals of Oncology|2015Cited by 4